Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model

Pharmaceutical Research

Volumn 23, Issue 8, 2006, Pages 1675-1686

  Cao, Xianhua ^a   Gibbs, Seth T ^a   Fang, Lanyan ^a   Miller, Heather A ^a   Landowski, Christopher P ^b   Shin, Ho Chul ^b   Lennernas, Hans ^c   Zhong, Yanqiang ^b   Amidon, Gordon L ^b   Yu, Lawrence X ^d   Sun, Duxin ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UPPSALA UNIVERSITY   (Sweden)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Drug transporter; Gene expression; Inter species correlation; Intestinal permeability; Metabolizing enzyme; Oral bioavailability

Indexed keywords

ATENOLOL; CARRIER PROTEIN; CEFALEXIN; CIMETIDINE; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; CYTOCHROME P450 3A9; ENALAPRIL; FUROSEMIDE; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 3; GLUCOSE TRANSPORTER 5; GLUTAMATE TRANSPORTER; KETOPROFEN; LEUCINE; LEVODOPA; MACROGOL 4000; METHYLDOPA; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3; PEPTIDE TRANSPORTER 1; PHENYLALANINE; PROPRANOLOL; PROTEIN NT2; SODIUM GLUCOSE COTRANSPORTER 1; UNCLASSIFIED DRUG; UNINDEXED DRUG; URIDINE DIPHOSPHATE GLUCOSE; VALACICLOVIR; VERAPAMIL;

ANIMAL TISSUE; ARTICLE; COLON; CONTROLLED STUDY; DIFFUSION; DNA MICROARRAY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG METABOLISM; DUODENUM; HUMAN; HUMAN TISSUE; INTESTINE ABSORPTION; INTESTINE MUCOSA PERMEABILITY; INTESTINE PERFUSION; JEJUNUM; NONHUMAN; PRIORITY JOURNAL; RAT; SMALL INTESTINE; SPECIES DIFFERENCE;

ANIMALS; BIOLOGICAL AVAILABILITY; CARRIER PROTEINS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLON; DATA INTERPRETATION, STATISTICAL; DUODENUM; HUMANS; INTESTINAL ABSORPTION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PERFUSION; PERMEABILITY; PHARMACEUTICAL PREPARATIONS; PREDICTIVE VALUE OF TESTS; RATS; RATS, SPRAGUE-DAWLEY; RNA; RNA, COMPLEMENTARY; SPECIES SPECIFICITY;

EID: 33746903600     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-006-9041-2     Document Type: Article

References (83)

1. S. M. Pond and T. N. Tozer. First-pass elimination. Basic concepts and clinical consequences. Clin. Pharmacokinet. 9:1-25 (1984).
2. C. L. Cummins, W. Jacobsen, and L. Z. Benet. Unmasking the dynamic interplay between intestinal P-glycoprotein and C-P3A4. J. Pharmacol. Exp. Ther. 300:1036-1045 (2002).
3. G. L. Amidon, H. Lennernas, V. P. Shah, and J. R. Crison. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12:413-420 (1995).
4. H. Lennernas. Human intestinal permeability. J. Pharm. Sci. 87:403-410 (1998).
5. W. L. Chiou. The validation of the intestinal permeability approach to predict oral fraction of dose absorbed in humans and rats. Biopharm. Drug Dispos. 16:71-75 (1995).
6. D. Sun, H. Lennernas, L. S. Welage, J. L. Barnett, C. P. Landowski, D. Foster, D. Fleisher, K. D. Lee, and G. L. Amidon. Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs. Pharm. Res. 19:1400-1416 (2002).
7. D. Sun, L. X. Yu, M. A. Hussain, D. A. Wall, R. L. Smith, and G. L. Amidon. In vitro testing of drug absorption for drug 'developability' assessment: forming an interface between in vitro preclinical data and clinical outcome. Curr. Opin. Drug Discov. Devel. 7:75-85 (2004).
8. W. Rubas, N. Jezyk, and G. M. Grass. Comparison of the permeability characteristics of a human colonic epithelial (Caco-2) cell line to colon of rabbit, monkey, and dog intestine and human drug absorption. Pharm. Res. 10:113-118 (1993).
9. Y. H. Zhao, M. H. Abraham, J. Le, A. Hersey, C. N. Luscombe, G. Beck, B. Sherborne, and I. Cooper. Evaluation of rat intestinal absorption data and correlation with human intestinal absorption. Eur. J. Med. Chem. 38:233-243 (2003).
10. W. L. Chiou and A. Barve. Linear correlation of the fraction of oral dose absorbed of 64 drugs between humans and rats. Pharm. Res. 15:1792-1795 (1998).
11. E. Watanabe, M. Takahashi, and M. Hayashi. A possibility to predict the absorbability of poorly water-soluble drugs in humans based on rat intestinal permeability assessed by an in vitro chamber method. Eur. J. Pharm. Biopharm. 58:659-665 (2004).
12. U. Fagerholm, L. Borgstrom, O. Ahrenstedt, and H. Lennernas. The lack of effect of induced net fluid absorption on the in vivo permeability of terbutaline in the human jejunum. J. Drug Target. 3:191-200 (1995).
13. U. Fagerholm, M. Johansson, and H. Lennernas. Comparison between permeability coefficients in rat and human jejunum. Pharm. Res. 13:1336-1342 (1996).
14. U. Fagerholm, D. Nilsson, L. Knutson, and H. Lennernas. Jejunal permeability in humans in vivo and rats in situ: investigation of molecular size selectivity and solvent drag. Acta Physiol. Scand. 165:315-324 (1999).
15. E. Krondahl, A. Orzechowski, G. Ekstrom, and H. Lennernas. Rat jejunal permeability and metabolism of mu-selective tetrapeptides in gastrointestinal fluids from humans and rats. Pharm. Res. 14:1780-1785 (1997).
16. C. P. Landowski, D. Sun, D. R. Foster, S. S. Menon, J. L. Barnett, L. S. Welage, C. Ramachandran, and G. L. Amidon. Gene expression in the human intestine and correlation with oral valacyclovir pharmacokinetic parameters. J. Pharmacol. Exp. Ther. 306:778-786 (2003).
17. H. Lennernas, O. Ahrenstedt, R. Hallgren, L. Knutson, M. Ryde, and L. K. Paalzow. Regional jejunal perfusion, a new in vivo approach to study oral drug absorption in man. Pharm. Res. 9:1243-1251 (1992).
18. H. Lennernas, S. Nylander, and A. L. Ungell. Jejunal permeability: a comparison between the ussing chamber technique and the single-pass perfusion in humans. Pharm. Res. 14:667-671 (1997).
19. D. Nilsson, U. Fagerholm, and H. Lennernas. The influence of net water absorption on the permeability of antipyrine and levodopa in the human jejunum. Pharm. Res. 11:1540-1547 (1994).
20. R. Sandstrom, A. Karlsson, L. Knutson, and H. Lennernas. Jejunal absorption and metabolism of R/S-verapamil in humans. Pharm. Res. 15:856-862 (1998).
21. R. Sandstrom, T. W. Knutson, L. Knutson, B. Jansson, and H. Lennernas. The effect of ketoconazole on the jejunal permeability and C-P3A metabolism of (R/S)-verapamil in humans. Br. J. Clin. Pharmacol. 48:180-189 (1999).
22. N. Takamatsu, L. S. Welage, N. M. Idkaidek, D. Y. Liu, P. I. Lee, Y. Hayashi, J. K. Rhie, H. Lennernas, J. L. Barnett, V. P. Shah, L. Lesko, and G. L. Amidon. Human intestinal permeability of piroxicam, propranolol, phenylalanine, and PEG 400 determined by jejunal perfusion. Pharm. Res. 14:1127-1132 (1997).
23. N. Takamatsu, O. N. Kim, L. S. Welage, N. M. Idkaidek, Y. Hayashi, J. Barnett, R. Yamamoto, E. Lipka, H. Lennernas, A. Hussain, L. Lesko, and G. L. Amidon. Human jejunal permeability of two polar drugs: cimetidine and ranitidine. Pharm. Res. 18:742-744 (2001).
24. S. Winiwarter, N. M. Bonham, F. Ax, A. Hallberg, H. Lennernas, and A. Karlen. Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach. J. Med. Chem. 41:4939-4949 (1998).
25. G. L. Amidon, M. Chang, D. Fleisher, and R. Allen. Intestinal absorption of amino acid derivatives: importance of the free alpha-amino group. J. Pharm. Sci. 71:1138-1141 (1982).
26. D. I. Friedman and G. L. Amidon. Passive and carrier-mediated intestinal absorption components of two angiotensin converting enzyme (ACE) inhibitor prodrugs in rats: enalapril and fosinopril. Pharm. Res. 6:1043-1047 (1989).
27. X. Y. Chu, G. P. Sanchez-Castano, K. Higaki, D. M. Oh, C. P. Hsu, and G. L. Amidon. Correlation between epithelial cell permeability of cephalexin and expression of intestinal oligopeptide transporter. J. Pharmacol. Exp. Ther. 299:575-582 (2001).
28. P. J. Sinko, G. D. Leesman, and G. L. Amidon. Predicting fraction dose absorbed in humans using a macroscopic mass balance approach. Pharm. Res. 8:979-988 (1991).
29. J. G. Hardman, L. E. Limbird, and A. G. Gilman. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10th ed. New York: Medical Publishing Division, McGraw-Hill, 2001.
30. S. Tamura, A. Ohike, R. Ibuki, L. Amidon Gordon, and S. Yamashita. Tacrolimus is a class II low-solubility high-permeability drug: the effect of P-glycoprotein efflux on regional permeability of tacrolimus in rats. J. Pharm. Sci. 91:719-729 (2002).
31. D. A. Richards. Comparative pharmacodynamics and pharmacokinetics of cimetidine and ranitidine. J. Clin. Gastroenterol. 5 (Suppl 1):81-90 (1983).
32. B. L. Kamath, A. Yacobi, S. D. Gupta, H. Stampfli, M. Durrani, and C.-M. Lai. Bioavailability of N-acetylprocainamide from mixed diet in rats. Res. Commun. Chem. Pathol. Pharmacol. 32:299-308 (1981).
33. R. Griffiths, R. M. Lee, and D. C. Taylor. Kinetics of cimetidine in man and experimental animals. Int. Congr. Ser. 416:38-53 (1977).
34. L. Cruz, G. Castaneda-Hernandez, and A. Navarrete. Ingestion of chili pepper (Capsicum annuum) reduces salicylate bioavailability after oral aspirin administration in the rat. Can. J. Physiol. Pharmacol. 77:441-446 (1999).
35. A. M. S. Ahmed, A. M. Moustafa, N. M. El-Abassawy, A. A. Ramadan, and M. I. Fetouh. HPLC evaluation and biovailability of nicardipine hydrochloride capsules and tablets. Al-Azhar J. Pharm. Sci. 25:116-129 (2000).
36. F. Berlioz, B. Lepere-Prevot, S. Julien, A. Tsocas, C. Carbon, C. Roze, and R. Farinotti. Chronic nifedipine dosing enhances cephalexin bioavailability and intestinal absorption in conscious rats. Drug Metab. Dispos. 28:1267-1269 (2000).
37. M. M. Bhatti and R. T. Foster. Pharmacokinetics of the enantiomers of verapamil after intravenous and oral administration of racemic verapamil in a rat model. Biopharm. Drug Dispos. 18:387-396 (1997).
38. S. J. Connolly and R. E. Kates. Clinical pharmacokinetics of N-acetylprocainamide. Clin. Pharmacokinet. 7:206-220 (1982).
39. B. Kaye, N. J. Cussans, J. K. Faulkner, and D. A. Stopher. The metabolism and kinetics of doxazosin in man, rat, mouse and dog. Br. J. Clin. Pharmacol. 21 (Suppl 1):19S-25S (1986).
40. K. L. Duchin, D. N. McKinstry, A. I. Cohen, and B. H. Migdalof. Pharmacokinetics of captopril in healthy subjects and in patients with cardiovascular diseases. Clin. Pharmacokinet. 14:241-259 (1988).
41. B. Dusterberg, M. Humpel, and U. Speck. Terminal half-lives in plasma and bioavailability of norethisterone, levonorgestrel, cyproterone acetate and gestodene in rats, beagles and rhesus monkeys. Contraception 24:673-683 (1981).
42. K. Fotherby. Levonorgestrel. Clinical pharmacokinetics. Clin. Pharmacokinet. 28:203-215 (1995).
43. M. R. Holdiness. Clinical pharmacokinetics of the antituberculosis drugs. Clin. Pharmacokinet. 9:511-544 (1984).
44. M. Humpel, T. Toda, N. Oshino, and G. Pommerenke. The pharmacokinetics of lisuride hydrogen maleate in rat, rabbit and rhesus monkey. Eur. J. Drug Metab. Pharmacokinet. 6:207-219 (1981).
45. M. A. Hussain, B. J. Aungst, and E. Shefter. Buccal and oral bioavailability of nalbuphine in rats. J. Pharm. Sci. 75:218-219 (1986).
46. F. Jamali and D. R. Brocks. Clinical pharmacokinetics of ketoprofen and its enantiomers. Clin. Pharmacokinet. 19:197-217 (1990).
47. R. P. Kapil, J. E. Axelson, R. Ongley, and J. D. Price. Nonlinear bioavailability of metoclopramide in the rat: evidence for saturable first-pass metabolism. J. Pharm. Sci. 73:215-218 (1984).
48. W. Krause and G. Kuhne. Pharmacokinetics of mepindolol sulfate in the rat, dog, and rhesus monkey. Studies on species differences. Drug Metab. Dispos. 11:91-96 (1983).
49. K. C. Kwan, E. L. Foltz, G. O. Breault, J. E. Baer, and J. A. Totaro. Pharmacokinetics of methyldopa in man. J. Pharmacol. Exp. Ther. 198:264-277 (1976).
50. R. M. Major, T. Taylor, L. F. Chasseaud, A. Darragh, and R. F. Lambe. Isosorbide 5-mononitrate kinetics. Clin. Pharmacol. Ther. 35:653-659 (1984).
51. D. McTavish and E. M. Sorkin. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension. Drugs 38:19-76 (1989).
52. R. Mehvar, F. Jamali, M. W. Watson, and D. Skelton. Pharmacokinetics of tetrabenazine and its major metabolite in man and rat. Bioavailability and dose dependency studies. Drug Metab. Dispos. 15:250-255 (1987).
53. Y. Nakai, K. Yamamoto, K. Terada, H. Horibe, and K. Ozawa. Interaction of tri-O-methyl-beta-cyclodextrin with drugs. II. Enhanced bioavailability of ketoprofen in rats when administered with tri-O-methyl-beta-cyclodextrin. Chem. Pharm. Bull. (Tokyo) 31:3745-3747 (1983).
54. C. J. Needs and P. M. Brooks. Clinical pharmacokinetics of the salicylates. Clin. Pharmacokinet. 10:164-177 (1985).
55. T. Ogiso, M. Iwaki, and E. Tamaki. Bioavailability of indomethacin calcium and magnesium, and effect of the salts on drug metabolizing enzyme activities in rats. J. Pharmacobiodyn. 6:803-813 (1983).
56. K. T. Olkkola, A. V. Brunetto, and M. J. Mattila. Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. Clin. Pharmacokinet. 26:107-120 (1994).
57. C. Prandi, P. Fagiolino, E. Manta, and L. Dominguez Llera. Bioavailability study of furosemide prodrugs in rats. Farmaco 47:1225-1234 (1992).
58. E. J. Seaber, R. W. Peck, D. A. Smith, J. Allanson, N. R. Hefting, J. J. van Lier, F. A. Sollie, J. Wemer, and J. H. Jonkman. The absolute bioavailability and effect of food on the pharmacokinetics of zolmitriptan in healthy volunteers. Br. J. Clin. Pharmacol. 46:433-439 (1998).
59. S. M. Singhvi, K. J. Kripalani, A. V. Dean, G. R. Keim, J. S. Kulesza, F. S. Meeker, J. J. Ross Jr, J. M. Shaw, and B. H. Migdalof. Absorption and bioavailability of captopril in mice and rats after administration by gavage and in the diet. J. Pharm. Sci. 70:885-888 (1981).
60. M. Strolin Benedetti and D. A. Larue. Bioavailability of codeine preparations in the rat. Arzneimittelforschung 23:826-828 (1973).
61. A. E. Thomsen, M. S. Christensen, M. A. Bagger, and B. Steffansen. Acyclovir prodrug for the intestinal di/tri-peptide transporter PEPT1: comparison of in vivo bioavailability in rats and transport in Caco-2 cells. Eur. J. Pharm. Sci. 23:319-325 (2004).
62. J. A. Young and K. D. Edwards. Studies on the absorption, metabolism and excretion of methyldopa and other catechols and their influence on amino acid transport in rats. J. Pharmacol. Exp. Ther. 145:102-112 (1964).
63. W. L. Chiou and P. W. Buehler. Comparison of oral absorption and bioavailability of drugs between monkey and human. Pharm. Res. 19:868-874 (2002).
64. I. de Waziers, P. H. Cugnenc, C. S. Yang, J. P. Leroux, and P. H. Beaune. Cytochrome P 450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J. Pharmacol. Exp. Ther. 253:387-394 (1990).
65. C. P. Strassburg, S. Kneip, J. Topp, P. Obermayer-Straub, A. Barut, R. H. Tukey, and M. P. Manns. Polymorphic gene regulation and interindividual variation of UDP-glucuronosyltransferase activity in human small intestine. J. Biol. Chem. 275:36164-36171 (2000).
66. G. Fricker, J. Drewe, J. Huwyler, H. Gutmann, and C. Beglinger. Relevance of p-glycoprotein for the enteral absorption of cyclosporin A: in vitro-in vivo correlation. Br. J. Pharmacol. 118:1841-1847 (1996).
67. S. A. Adibi. The oligopeptide transporter (Pept-1) in human intestine: biology and function. Gastroenterology 113:332-340 (1997).
68. H. Ogihara, H. Saito, B. C. Shin, T. Terado, S. Takenoshita, Y. Nagamachi, K. Inui, and K. Takata. Immuno-localization of H+/peptide cotransporter in rat digestive tract. Biochem. Biophys. Res. Commun. 220:848-852 (1996).
69. W. S. Kim, Y. Y. Kim, S. J. Jang, K. Kimm, and M. H. Jung. Glucose transporter 1 (GLUT1) expression is associated with intestinal type of gastric carcinoma. J. Korean Med. Sci. 15:420-424 (2000).
70. T. Nakamura, T. Sakaeda, N. Ohmoto, T. Tamura, N. Aoyama, T. Shirakawa, T. Kamigaki, T. Nakamura, I. Kim Ke, R. Kim Soo, Y. Kuroda, M. Matsuo, M. Kasuga, and K. Okumura. Real-time quantitative polymerase chain reaction for MDR1, MRP1, MRP2, and C-P3A-mRNA levels in Caco-2 cell lines, human duodenal enterocytes, normal colorectal tissues, and colorectal adenocarcinomas. Drug Metab. Dispos. 30:4-6 (2002).
71. C. Zimmermann, H. Gutmann, P. Hruz, J.-P. Gutzwiller, C. Beglinger, and J. Drewe. Mapping of multidrug resistance gene 1 and multidrug resistance-associated protein isoform 1 to 5 mRNA expression along the human intestinal tract. Drug Metab. Dispos. 33:219-224 (2005).
72. D. Rost, S. Mahner, Y. Sugiyama, and W. Stremmel. Expression and localization of the multidrug resistance-associated protein 3 in rat small and large intestine. Am. J. Physiol. 82:G720-G726 (2002).
73. Y. Kiuchi, H. Suzuki, T. Hirohashi, C. A. Tyson, and Y. Sugiyama. cDNA cloning and inducible expression of human multidrug resistance associated protein 3 (MRP3). FEBS Lett. 433:149-152 (1998).
74. V. J. Wacher, C. Y. Wu, and L. Z. Benet. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinog. 13:129-134 (1995).
75. G. Jedlitschky, I. Leier, U. Buchholz, J. Hummel-Eisenbeiss, B. Burchell, and D. Keppler. ATP-dependent transport of bilirubin glucuronides by the multidrug resistance protein MRP1 and its hepatocyte canalicular isoform MRP2. Biochem. J. 327(Pt1):305-310 (1997).
76. Q.-Y. Zhang, D. Dunbar, A. Ostrowska, S. Zeisloft, J. Yang, and L. S. Kaminsky. Characterization of human small intestinal cytochromes P-450. Drug Metab. Dispos. 27:804-809 (1999).
77. J. C. Kolars, P. Schmiedlin-Ren, J. D. Schuetz, C. Fang, and P. B. Watkins. Identification of rifampin-inducible P450IIIA4 (C-P3A4) in human small bowel enterocytes. J. Clin. Invest. 90:1871-1878 (1992).
78. M. F. Paine, M. Khalighi, J. M. Fisher, D. D. Shen, K. L. Kunze, C. L. Marsh, J. D. Perkins, and K. E. Thummel. Characterization of interintestinal and intraintestinal variations in human C-P3A-dependent metabolism. J. Pharmacol. Exp. Ther. 283:1552-1562 (1997).
79. J. C. Kolars, K. S. Lown, P. Schmiedlin-Ren, M. Ghosh, C. Fang, S. A. Wrighton, R. M. Merion, and P. B. Watkins. C-P3A gene expression in human gut epithelium. Pharmacogenetics 4:247-259 (1994).
80. K. Takara, N. Ohnishi, S. Horibe, and T. Yokoyama. Expression profiles of drug-metabolizing enzyme C-P3A and drug efflux transporter multidrug resistance 1 subfamily mRNAs in rat small intestine. Drug Metab. Dispos. 31:1235-1239 (2003).
81. M. Lindell, M. Lang, and H. Lennernas. Expression of genes encoding for drug metabolising cytochrome P450 enzymes and P-glycoprotein in the rat small intestine; comparison to the liver. Eur. J. Drug Metab. Pharmacokinet. 28:41-48 (2003).
82. A. S. Koster, A. C. Frankhuijzen-Sierevogel, and J. Noordhoek. Distribution of glucuronidation capacity (1-naphthol and morphine) along the rat intestine. Biochem. Pharmacol. 34:3527-3532 (1985).
83. J. H. Lin, M. Chiba, and T. A. Baillie. Is the role of the small intestine in first-pass metabolism overemphasized? Pharmacol. Rev. 51:135-158 (1999).